HONG KONG – Chinese vaccine developer Yisheng Biopharma Co. Ltd. is looking at Southeast Asian markets as the first big opportunity for the company’s rabies vaccine, but any marketing will not happen for at least two years.
HONG KONG – Chinese vaccine developer Yisheng Biopharma Co. Ltd. is looking at Southeast Asian markets as the first big opportunity for the company's rabies vaccine, but any marketing will not happen for at least two years.
HONG KONG — Medical devices are among 201 technology products that account for an estimated $1.3 trillion in annual trade and will not be subject to customs duties beginning next year as the Information Technology Agreement (ITA) among members of the World Trade Organization (WTO) marks a landmark expansion.
HONG KONG – Even as Asian markets wobble and investors scrutinize every move, Chinese drugmaker Yichang HEC Changjiang Pharmaceutical Co. Ltd., which focuses on developing, manufacturing and selling antiviral medicines, launched an IPO in Hong Kong Monday looking to raise as much as HK$1.67 billion (US$215 million).
HONG KONG – Even as Asian markets wobble and investors scrutinize every move, Chinese drugmaker Yichang HEC Changjiang Pharmaceutical Co. Ltd., which focuses on developing, manufacturing and selling antiviral medicines, launched an IPO in Hong Kong Monday looking to raise as much as HK$1.67 billion (US$215 million).
HONG KONG – The chill of a wide-ranging anti-corruption campaign in China that has led to some very high-profile arrests spread with news that Guo Guangchang, the chairman of Fosun International Ltd., may have been snared in a corruption investigation. Shares of its subsidiary, Fosun Pharmaceutical Group Co. Ltd. (HKEX:2196, SS:600196), plunged more than 12 percent Monday on the Hong Kong stock exchange and about 4 percent in Shanghai.
HONG KONG – The chill of a wide-ranging anti-corruption campaign in China that has led to some very high-profile arrests spread with news that Guo Guangchang, the chairman of Fosun International Ltd., may have been snared in a corruption investigation. Shares of its subsidiary, Fosun Pharmaceutical Group Co. Ltd. (HKEX:2196, SS:600196), plunged more than 12 percent Monday on the Hong Kong stock exchange and about 4 percent in Shanghai.
